Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-alpha-n1 With or Without Chemotherapy and Autografting in Newly Diagnosed CML
NCT00002868Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Nov 1997
- Primary completion
- Mar 2004
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of interferon alfa in chronic myelogenous leukemia (CML) (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Overall Survival. Started Nov 1997; status: completed.
02
Drugs
interferon alfa
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00002868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002868.